Impaired acetylcholine-induced cutaneous vasodilation in young smokers: roles of nitric oxide and prostanoids
| Autor: | Christopher T. Minson, Maggie Cooper Reinke, Naoto Fujii, Vienna E. Brunt |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Mean arterial pressure Microdialysis Physiology Vascular Biology and Microcirculation Vasodilator Agents Vasodilation Nitric Oxide Nitric oxide Young Adult chemistry.chemical_compound Physiology (medical) Internal medicine Laser-Doppler Flowmetry medicine Humans Cyclooxygenase Inhibitors Enzyme Inhibitors Skin biology business.industry Microcirculation Smoking Area under the curve equipment and supplies Acetylcholine Skin Aging Ketorolac NG-Nitroarginine Methyl Ester Endocrinology chemistry Prostaglandin-Endoperoxide Synthases Anesthesia Prostaglandins biology.protein Female Sodium nitroprusside Cyclooxygenase Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | American Journal of Physiology-Heart and Circulatory Physiology. 304:H667-H673 |
| ISSN: | 1522-1539 0363-6135 |
| DOI: | 10.1152/ajpheart.00731.2012 |
| Popis: | Cigarette smoking attenuates acetylcholine (ACh)-induced cutaneous vasodilation in humans, but the underlying mechanisms are unknown. We tested the hypothesis that smokers have impaired nitric oxide (NO)- and cyclooxygenase (COX)-dependent cutaneous vasodilation to ACh infusion. Twelve young smokers, who have smoked more than 5.2 ± 0.7 yr with an average daily consumption of 11.4 ± 1.2 cigarettes, and 12 nonsmokers were tested. Age, body mass index, and resting mean arterial pressure were similar between the groups. Cutaneous vascular conductance (CVC) was evaluated as laser-Doppler flux divided by mean arterial pressure, normalized to maximal CVC (local heating to 43.0°C plus sodium nitroprusside administration). We evaluated the increase in CVC from baseline to peak (CVCΔpeak) and area under the curve of CVC (CVCAUC) during a bolus infusion (1 min) of 137.5 μM ACh at four intradermal microdialysis sites: 1) Ringer (control), 2) 10 mM NG-nitro-l-arginine methyl ester (l-NAME; NO synthase inhibitor), 3) 10 mM ketorolac (COX inhibitor), and 4) combination of l-NAME + ketorolac. CVCΔpeakand CVCAUCat the Ringer site in nonsmokers were greater than in smokers (CVCΔpeak, 42.9 ± 5.1 vs. 22.3 ± 3.5%max, P < 0.05; and CVCAUC, 8,085 ± 1,055 vs. 3,145 ± 539%max·s, P < 0.05). In nonsmokers, CVCΔpeakand CVCAUCat the l-NAME site were lower than the Ringer site (CVCΔpeak, 29.5 ± 6.2%max, P < 0.05; and CVCAUC, 5,377 ± 1,109%max·s, P < 0.05), but in smokers, there were no differences between the Ringer and l-NAME sites (CVCΔpeak, 16.8 ± 4.3%max, P = 0.11; and CVCAUC, 2,679 ± 785%max·s, P = 0.30). CVCΔpeakand CVCAUCwere reduced with ketorolac in nonsmokers (CVCΔpeak, 13.3 ± 3.6%max, P < 0.05; and CVCAUC, 1,967 ± 527%max·s, P < 0.05) and smokers (CVCΔpeak, 7.8 ± 1.8%max, P < 0.05; and CVCAUC, 1,246 ± 305%max·s, P < 0.05) and at the combination site in nonsmokers (CVCΔpeak, 15.9 ± 3.1%max, P < 0.05; and CVCAUC, 2,660 ± 512%max·s, P < 0.05) and smokers (CVCΔpeak, 11.5 ± 2.6%max, P < 0.05; and CVCAUC, 1,693 ± 409%max·s, P < 0.05), but the magnitudes were greater in nonsmokers ( P < 0.05). These results suggest that impaired ACh-induced skin vasodilation in young smokers is related to diminished NO- and COX-dependent vasodilation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|